A clinicаl triаl is investigаting the effectiveness оf Erzоfri (paliperidоne), an extended-release injection for the treatment of schizophrenia. It considered the number of patients experiencing a relapse in symptoms compared to established treatment. The results of the trial are summarised below: Absolute risk of relapse in the Erzofri group (ARC) Absolute risk of relapse in the control group (ART) Occurrence of recurrent stroke 0.022 0.04 How many patients will need to be treated with Erzofri to prevent one relapse in schizophrenia symptoms? ARC = the absolute risk of events in the control groupART = the absolute risk of events in the treatment groupARR (absolute risk reduction) = ARC – ARTRRR (relative risk reduction) = (ARC – ART) / ARC NNT (number needed to treat) = 1 / ARR